Molbio Diagnostics has raised $183.3M across 2 funding rounds. The company is valued at $1B (post-money).
Molbio Diagnostics reached a valuation above $1 billion in 2022 after an $85 million investment from Temasek Holdings. The company has since converted into a public limited company and filed a draft red herring prospectus for an initial public offering in India.
2 funding rounds, the latest highlighted.
Molbio Diagnostics was founded in 2000, India.
A primary round — the company sells new shares to investors it selects. $85M raised, led by Temasek Holdings.
Listed company.
2 dated rounds, newest first.
Temasek HoldingsLEADThe closest medical diagnostics / molecular diagnostics peers are on the competitors page.
The routes section explains what is realistically available for a company at this stage.
Yes. Molbio Diagnostics is listed on BSE/NSE as MOLBIO.
The last valuation is $1B.
Lead investors for each round are in the funding timeline.
Perpetual markets for stocks, gold, indices and pre-IPO names — settled on-chain, no wallet-to-exchange transfers.
